We will now publish more news in English – and offer yet another newsletter

Starting next week, Life Science Sweden will begin offering a newsletter entirely in English.

ZEISS Quality Innovation Days: April 15 – 19, 2024

Be there when industry experts give exciting insights into different applications and trends in 90 minutes on various theme days.

Tablet treatment for hair loss approved in the USA

The US Drug Administration has given a thumbs up for the first tablet treatment for spotty hair loss.

3 000 ska bort från Australiens största läkemedelsbolag

Det australiensiska läkemedelsjätten CSL genomför sparåtgärder. I planen ingår bland annat att knoppa av bolagets vaccinenhet och minska arbetsstyrkan med 3 000 medarbetare.

Samuel Lagercrantz: Immunotherapy against cancer is still in its early stages

For more than 100 years, researchers have tried to target the body’s own immune system to fight cancer cells. They have occasionally been laughed at and ridicul...

MedVasc and Scientific Solutions join forces to streamline FDA 510(k) regulatory process

MedVasc, an exciting MedTech startup company, and Scientific Solutions, a renowned consulting firm within Life Science, are pleased to announce a strategic part...

ZEN core now available for all ZEISS scanning electron microscopes

Introducing intuitive, streamlined SEM control over imaging, analytics, and multi-modal workflows.

Stockholm aims at becoming one of the world’s top life science regions

Regional Chair for Finance, Irene Svenonius (M), believes that Stockholm can realise the goal of becoming one of the world’s top 5 regions in life science by 20...

Tirzepatide approved for obesity by the FDA – to be branded as Zepbound

Diabetes drug tirzepatide has now also been approved in the US for treating obesity.

KI-forskare har upptäckt biomarkörer för postcovid

Forskare vid Karolinska institutet har i en ny studie identifierat en uppsättning proteiner i blod hos personer med långvariga besvär av postcovid.

Anna Törner: Success requires bold decisions!

“Doing things right is fine, but doing the right things as soon as possible is even better”, writes Anna Törner in a column.

Investments worth 40 billion in the Öresund region – “A huge investment wave”

A new report reveals that medical companies in the Oresund region are investing like never before.

Lucy Robertshaw: There is a bio revolution happening right now

Lucy Robertshaw is both proud and excited to be taking the baton of moderating this year’s Pharma Outsourcing event.

Medical Applications

Video about metrology solutions for medical components

Nanexa develops depot formulation of the diabetes and obesity drug Saxenda

Uppsala-based company Nanexa has signed an agreement with a German contract research company to start a clinical study with a monthly depot of liraglutide. The ...

Webinar: Clinical evaluation and clinical investigation of medical devices

Whether you are a small medtech company or a large one, this webinar is a must-attend for anyone curious about how clinical studies on medical devices are conducted.

Giulia Gaudenzi: Innovation for good

"I challenge the innovator landscape to take a mental leap. Relying on innovation-solely to end inequality is not enough, therefore consciously and purposively ...

A new international stem cell research centre has been created in Copenhagen

A new centre for stem cell research opened to the public in January. The Novo Nordisk Foundation backs the initiative with the ambition that the centre will adv...

The first vaccine derived from cowpox

The British rural doctor could not forget the words of the peasant girl. Could that really be true? A couple of decades later, on 14 May 1796, he performed the ...

“Together Stockholm-Uppsala and Medicon Valley can make Scandinavia a leading life science region”

“Denmark, Sweden, Norway and Finland all have national life science strategies, but the Swedish strategy is the only one explicitly emphasizing the Nordic dimen...

Science to Market - S2M

Marie Gårdmark: Do EMA and FDA talk to each other?

Of course they do! The collaboration started already in 2003, writes Marie Gårdmark in a column.

The first pharmaceutical for eosinophilic esophagitis approved in the U.S.

The U.S. Drug Administration has approved the drug Dupixent (dupilumab) to treat inflammation of the oesophagus of the type eosinophil esophagitis.

CROs in drug development: "We use our expertise to speed up the process

Consultancy firms have become an increasingly important part of drug development. “It’s a trend and a business model that works, and we see no indication that i...